Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

ALCIDION GROUP LIMITED Director's Dealing 2018

Apr 30, 2018

64360_rns_2018-04-30_b2f55238-eda5-4011-b8ac-3272d99656e4.pdf

Director's Dealing

Open in viewer

Opens in your device viewer

==> picture [123 x 36] intentionally omitted <==

1 May 2018

Australian Securities Exchange 20 Bridge Street, Sydney NSW 2000

Alcidion Appendix 3Y Notifications

Adelaide, South Australia, 1 May 2018 - Alcidion Group Limited (ASX: ALC ), has today lodged Appendix 3Y notifications relating to the purchase of shares by the following directors or their associates: Ray Blight (3.02 million shares), Rebecca Wilson (570,000 shares) and Geoff Rohrsheim (1 million shares).

The directors were previously restricted from purchasing shares due to a trading blackout in place whilst the acquisition of MKM Health and Patientrack, announced to the market last week, was being negotiated.

Ray Blight, CEO of Alcidion Group said, “I am pleased to increase my position as a shareholder, and to welcome two of our Directors as fellow shareholders of the company. It has been their intention to buy shares and, now that trading restrictions have been lifted, they have promptly followed through with this. The MKM acquisition is transformative and we look forward to presenting to investors at our roadshow underway this week.”

### ENDS ###

For further information, please contact: Ray Blight, Chief Executive Officer Kyahn Williamson, WEBuchan Ph: +61 (08) 8208 4600 Ph: 0401018828 Alcidion Group Limited [email protected] [email protected]

About Alcidion

Alcidion Group Limited (ASX:ALC) is a publicly listed, innovative health informatics company that specializes in clinical products that improve productivity, safety and efficiency. Alcidion’s solutions target key problems for Emergency Rooms, Inpatient Services and Outpatient Departments and are built upon a next generation health informatics platform, which incorporates an intelligent EMR, Clinical Decision Support Engine, Data Integration Capability, Smartforms, Terminology Support and Standards Based Web Services.

Alcidion’s focus is on delivering solutions that enable high performance healthcare and which assist clinicians by minimising key clinical risks, tracking patient progress through journeys and improving quality and safety of patient care.

www.alcidion.com

© Alcidion Group Limited 2018. Alcidion and Miya are registered trademarks. All other brands and product names and trademarks are the registered property of their respective companies.

==> picture [595 x 9] intentionally omitted <==

[email protected] | www.alcidion.com 40 Greenhill Road | Wayville SA | Australia |  +61 1800 767 873 | � +61 8 8271 2644

Appendix 3Y Change of Director’s Interest Notice

Rule 3.19A.2

Appendix 3Y

Change of Director’s Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity ALCIDION GROUP LIMITED
ABN 77 143 142 410

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director RAYMOND HOWARD BLIGHT
Date of last notice 23/12/2016

Part 1 - Change of director’s relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

Direct or indirect interest DIRECT & INDIRECT
Nature of indirect interest
(including registered holder)
Note: Provide details of the circumstances giving rise to the relevant
interest.
SHARES HELD BY SPOUSE (ROBYN GAILE
MORRIS)
Date of change 24-27 April 2018
No. of securities held prior to change 97,051,004
Class FULLY PAID ORDINARY SHARES
Number acquired 3,020,000
Number disposed NIL
Value/Consideration
Note: If consideration is non-cash, provide details and estimated
valuation
$129,172
No. of securities held after change 100,071,004 FULLY PAID ORDINARY SHARES
-
  • See chapter 19 for defined terms.

01/01/2011

Appendix 3Y Page 1

Appendix 3Y Change of Director’s Interest Notice

Nature of change ON-MARKET TRADES Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buyback

Part 2 – Change of director’s interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract N/A
Nature of interest N/A
Name of registered holder
(if issued securities)
N/A
Date of change N/A
No. and class of securities to
which interest related prior to
change
Note: Details are only required for a contract in
relation to which the interest has changed
N/A
Interest acquired N/A
Interest disposed N/A
Value/Consideration
Note: If consideration is non-cash, provide details and
an estimated valuation
N/A
Interest after change N/A

Part 3 –[+] Closed period

Were the interests in the securities or contracts detailed
above traded during a+closed period where prior written
clearance was required?
NO
If so, was prior written clearance provided to allow the
trade to proceed during this period?
N/A
If prior written clearance was provided, on what date was
this provided?
N/A
  • See chapter 19 for defined terms.

Appendix 3Y Page 2

01/01/2011

==> picture [123 x 37] intentionally omitted <==

1 May 2018

Australian Securities Exchange 20 Bridge Street Sydney NSW 2000

Appendix 3Y

Change of Director’s Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity ALCIDION GROUP LIMITED
ABN 77 143 142 410

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director GEOFF ROHRSHEIM
Date of last notice 31/07/2017

Part 1 - Change of director’s relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

Direct or indirect interest INDIRECT
Nature of indirect interest
(including registered holder)
Note: Provide details of the circumstances giving rise to
the relevant interest.
G R ROHRSHEIM NOMINEES PTY LTD ATF
ROHRSHEIM SUPER FUND
Date of change 26 APRIL 2018
No. of securities held prior to change NIL
Class FULLY PAID ORDINARY SHARES
Number acquired 1,000,000 FULLY PAID ORDINARY SHARES
Number disposed -

[email protected] | www.alcidion.com 40 Greenhill Road | Wayville SA | Australia |  +61 1800 767 873 | � +61 8 8271 2644

==> picture [123 x 37] intentionally omitted <==

Value/Consideration
Note: If consideration is non-cash, provide
details and estimated valuation
$40,621.15 PAID FOR FULLY PAID ORDINARY
SHARES
No. of securities held after change 1,000,000 FULLY PAID ORDINARY SHARES
Nature of change
Example: on-market trade, off-market trade,
exercise of options, issue of securities under
dividend reinvestment plan, participation in
buy-back
ON-MARKET TRADE

Part 2 – Change of director’s interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract N/A
Nature of interest N/A
Name of registered holder
(if issued securities)
N/A
Date of change N/A
No. and class of securities to which
interest related prior to change
Note: Details are only required for
a contract in relation to which the
interest has changed
N/A
Interest acquired N/A
Interest disposed N/A

[email protected] | www.alcidion.com 40 Greenhill Road | Wayville SA | Australia |  +61 1800 767 873 | � +61 8 8271 2644

==> picture [123 x 37] intentionally omitted <==

Value/Consideration
Note: If consideration is non-cash,
provide details and an estimated
valuation
N/A
Interest after change N/A

Part 3 –[+] Closed period

Were the interests in the securities or contracts detailed
above traded during a+closed period where prior written
clearance was required?
No
If so, was prior written clearance provided to allow the
trade to proceed during this period?
N/A
If prior written clearance was provided, on what date was
this provided?
N/A

### ENDS ###

For further information, please contact:

Duncan Craig

Chief Financial Officer and Company Secretary Ph: +61 (08) 8208 4600 Alcidion Corporation [email protected]

About Alcidion

Alcidion Group Limited (ASX:ALC) is a publicly listed, innovative health informatics company that specializes in clinical products that improve productivity, safety and efficiency. Alcidion’s solutions target key problems for Emergency Rooms, Inpatient Services and Outpatient Departments and are built upon a next generation health informatics platform, which incorporates an intelligent EMR, Clinical Decision Support Engine, Data Integration Capability, Smartforms, Terminology Support and Standards Based Web Services.

Alcidion’s focus is on delivering solutions that enable high performance healthcare and which assist clinicians by minimising key clinical risks, tracking patient progress through journeys and improving quality and safety of patient care.

www.alcidion.com

© Alcidion Group Limited 2017. Alcidion and Miya are registered trademarks. All other brands and product names and trademarks are the registered property of their respective companies

[email protected] | www.alcidion.com 40 Greenhill Road | Wayville SA | Australia |  +61 1800 767 873 | � +61 8 8271 2644

==> picture [123 x 37] intentionally omitted <==

1 May 2018

Australian Securities Exchange 20 Bridge Street Sydney NSW 2000

Appendix 3Y

Change of Director’s Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity ALCIDION GROUP LIMITED
ABN 77 143 142 410

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director REBECCA WILSON
Date of last notice 31/07/2017

Part 1 - Change of director’s relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

Direct or indirect interest DIRECT
Nature of indirect interest
(including registered holder)
Note: Provide details of the circumstances giving rise to
the relevant interest.
Date of change 27APRIL 2018
No. of securities held prior to change NIL
Class FULLY PAID ORDINARY SHARES
Number acquired 570,000 FULLY PAID ORDINARY SHARES
Number disposed -

[email protected] | www.alcidion.com 40 Greenhill Road | Wayville SA | Australia |  +61 1800 767 873 | � +61 8 8271 2644

==> picture [123 x 37] intentionally omitted <==

Value/Consideration
Note: If consideration is non-cash, provide
details and estimated valuation
$25,080 PAID FOR FULLY PAID ORDINARY
SHARES
No. of securities held after change 570,000 FULLY PAID ORDINARY SHARES
Nature of change
Example: on-market trade, off-market trade,
exercise of options, issue of securities under
dividend reinvestment plan, participation in
buy-back
ON-MARKET TRADES

Part 2 – Change of director’s interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract N/A
Nature of interest N/A
Name of registered holder
(if issued securities)
N/A
Date of change N/A
No. and class of securities to which
interest related prior to change
Note: Details are only required for
a contract in relation to which the
interest has changed
N/A
Interest acquired N/A
Interest disposed N/A

[email protected] | www.alcidion.com 40 Greenhill Road | Wayville SA | Australia |  +61 1800 767 873 | � +61 8 8271 2644

==> picture [123 x 37] intentionally omitted <==

Value/Consideration
Note: If consideration is non-cash,
provide details and an estimated
valuation
N/A
Interest after change N/A

Part 3 –[+] Closed period

Were the interests in the securities or contracts detailed
above traded during a+closed period where prior written
clearance was required?
No
If so, was prior written clearance provided to allow the
trade to proceed during this period?
N/A
If prior written clearance was provided, on what date was
this provided?
N/A

### ENDS ###

For further information, please contact:

Duncan Craig

Chief Financial Officer and Company Secretary Ph: +61 (08) 8208 4600 Alcidion Corporation [email protected]

About Alcidion

Alcidion Group Limited (ASX:ALC) is a publicly listed, innovative health informatics company that specializes in clinical products that improve productivity, safety and efficiency. Alcidion’s solutions target key problems for Emergency Rooms, Inpatient Services and Outpatient Departments and are built upon a next generation health informatics platform, which incorporates an intelligent EMR, Clinical Decision Support Engine, Data Integration Capability, Smartforms, Terminology Support and Standards Based Web Services.

Alcidion’s focus is on delivering solutions that enable high performance healthcare and which assist clinicians by minimising key clinical risks, tracking patient progress through journeys and improving quality and safety of patient care.

www.alcidion.com

© Alcidion Group Limited 2017. Alcidion and Miya are registered trademarks. All other brands and product names and trademarks are the registered property of their respective companies

[email protected] | www.alcidion.com 40 Greenhill Road | Wayville SA | Australia |  +61 1800 767 873 | � +61 8 8271 2644